导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.46% | 3936/4773 |
| 近一周 | -2.53% | 4001/5465 |
| 近一月 | -2.76% | 1887/5421 |
| 近一季 | -2.55% | 1420/5231 |
| 近半年 | -4.53% | 2852/4920 |
| 近一年 | -15.77% | 3776/4394 |
| 近两年 | 27.74% | 2385/2954 |
| 近三年 | 8.60% | 1788/2253 |
| 成立以来 | 13.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.41% 4650/4961 |
8.55% 2581/5312 |
- - |
- - |
| 2025 | 3.42% 3124/4813 |
-6.67% 3384/3635 |
4.17% 839/4076 |
10.67% 3259/4524 |
-3.89% 3356/4813 |
| 2024 | 26.57% 221/3463 |
-4.70% 1744/2808 |
-8.24% 2195/3014 |
42.57% 47/3129 |
1.52% 1058/3463 |
| 2023 | 3.79% 262/2656 |
3.97% 1082/2280 |
-2.76% 653/2385 |
7.29% 52/2515 |
-4.31% 958/2655 |
| 2022 | -24.84% 1263/2207 |
-17.78% 1261/1919 |
2.07% 1366/2016 |
-15.43% 1290/2113 |
5.91% 412/2208 |
| 2021 | -4.63% 955/1822 |
-14.59% 1179/1255 |
6.85% 716/1330 |
2.89% 424/1466 |
1.57% 873/1822 |
| 2020 | 20.07% 724/1250 |
-9.68% 707/1028 |
9.61% 787/1067 |
19.97% 64/1164 |
1.10% 1043/1184 |
| 2019 | 45.39% 151/1092 |
45.84% 24/754 |
-6.01% 492/804 |
-3.97% 752/850 |
10.44% 130/918 |
| 2018 | -26.75% 397/834 |
- - |
- - |
- - |
-1.35% 12/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证全指证券公司ETF联接(LOF)A VS. 长安沪深300非周期A(740101) |